The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of ...
CHICAGO — For patients with pancreatic resectable stage I-Ill pancreatic ductal adenocarcinoma (PDAC), neoadjuvant chemotherapy can help improve overall survival compared with upfront surgery. But ...
A new blood test could change the outlook for one of the deadliest cancers—pancreatic cancer—by catching it much earlier than ...
A new UCLA investigator-initiated study has found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic ...
Last month, the United States Food and Drug Administration (FDA) approved a new wearable device for treating pancreatic ...
Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel ...
Surgery alone offered improved survival and a potential cure for select pancreatic cancer patients. Clear surgical margins and negative lymph node status were essential to better survival. The ...
Erratum: Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study The article by Fietkau et al entitled “Benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results